Skip to content
Menu

Jade Biosciences, Inc. JBIO

Full chart Compare
Set alert

Price alert · JBIO

All alert types
15.31 USD +0.25 (+1.66%)

Regular-session close

15.31 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

15.00 Day range 15.53
11.48 52-week range 26.85
YTD
-0.78%
1 year
+33.36%

 

No chart data for this range yet.
Market cap
1.06B
EPS (ttm)
-1.83
Shares out
69.19M
Forward P/E
-6.78
YTD return
-0.78%
1-year return
+33.36%
50-day average
15.00
200-day average
18.21
Enterprise value
567.02M
Volume
1.02M
Avg volume
910.19K
Open
15.00
Previous close
15.06
Day's range
15.00 – 15.53
52-week range
11.48 – 26.85
Analysts
Strong Buy
Price target
49.38 (+222.5%)
Earnings date
Mar 5, 2027

Key statistics

Price / book
2.25
Total cash
475.71M
Total debt
733.00K
Short % of float
18.71%

Fundamental scorecard

5 of 25 checks passed on JBIO’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
JBIO Revenue — quarterly 0
JBIO Net income — quarterly -35.05M
JBIO EPS — quarterly -0.42

Earnings

JBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 5, 2027Dec 30, 2026-0.64———
Nov 13, 2026Sep 30, 2026-0.73388-0.42+0.31+42.77%
Aug 10, 2026Jun 30, 2026-0.63642-0.76-0.12-19.42%
May 7, 2026Mar 31, 2026-0.52-0.57-0.05-9.62%
Mar 6, 2026Dec 31, 2025-0.45-0.450.000.00%
Nov 14, 2025Sep 30, 2025-0.57-0.48+0.09+15.79%

Upgrades / downgrades

JBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 16, 2026GuggenheimmainBuyBuy
Oct 27, 2026BTIGreitBuyBuy
Oct 1, 2026WedbushreitOutperformOutperform
Oct 1, 2026HC Wainwright & Co.reitBuyBuy
Aug 11, 2026WedbushmainOutperformOutperform
Aug 10, 2026BTIGmainBuyBuy

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on JBIO — it syncs with the Stock Master app.

Insider holders

JBIO insider holders
InsiderRelationLatest transactionDateShares held
BALTA ELIZABETHOfficerStock Award(Grant)Feb 11, 202628,125
DAHMS BRADFORD DChief Financial OfficerStock Award(Grant)Feb 11, 202637,813
FAIRMOUNT FUNDS MANAGEMENT LLCBeneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Oct 5, 20250
FROHLICH TOMChief Executive OfficerStock Award(Grant)Feb 11, 202686,331
KING ANDREW JAMESOfficerStock Award(Grant)Feb 11, 2026386,113

Institution ownership

JBIO institution ownership
Holder% heldSharesValueReported
FMR, LLC14.18%9,810,088150.19MSep 29, 2026
Janus Henderson Group Ltd.10.11%6,991,676107.04MSep 29, 2026
Paradigm Biocapital Advisors LP8.75%6,053,26892.68MSep 29, 2026
Fairmount Funds Management LLC6.58%4,553,49469.71MSep 29, 2026
Bellevue Group AG6.21%4,293,93765.74MSep 29, 2026
Franklin Templeton, Inc.5.50%3,807,23658.29MSep 29, 2026

Fund ownership

JBIO fund ownership
Holder% heldSharesValueReported
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.48%1,714,64026.25MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.46%1,699,34326.02MJun 29, 2026
Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND2.04%1,412,55921.63MJul 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.72%1,191,88418.25MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.49%1,032,64215.81MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.45%1,000,00015.31MSep 29, 2026